Potential Benefits and Value of Biosimilars
CLEAR

Potential Benefits & Value of Biosimilars

Biosimilars have the potential to have a positive impact on patients and the healthcare system. They can reduce costs by offering a lower-cost treatment option and provide more treatment options for patients.

How Biosimilars Save on Costs

Biosimilars introduce competition into the healthcare system. As the number of treatment choices increases for a particular disease or condition, manufacturers are incentivized to reduce the prices of their products to maintain or increase market share.

Learn more about their impact on cost savings

How Biosimilars Affect the Marketplace(1-4)

PotentialBenefitsCompetition2x 

The competition fostered by a marketplace with biosimilars could benefit every stakeholder in the healthcare system

PotentialBenefitsCostSavings2x 

Opportunity for system-wide cost savings

PotentialBenefitsInnovatorProducts2x 

Headroom for greater investment in innovator products

PotentialBenefitsTreatmentOptions2x 

More treatment options for patients with serious illnesses

PotentialBenefitsReducePrices2x 

Manufacturers incentivized to reduce prices

With rising healthcare costs, biosimilars contribute to a more sustainable healthcare system by providing patients with more treatment options.5

References

  1. Dolinar RO. Biosimilars are not generics. Endocrine Today. www.healio.com/endocrinology/practice-management/news/print/endocrinetoday/%7Bfd6accbd-a927-467b-ba5e-4f8796327816%7D/biosimilars-are-not-generics. Accessed August 1, 2022.
  2. Federal Trade Commission. Emerging health care issues: follow-on biologic drug competition. www.ftc.gov/os/2009/06/P083901biologicsreport.pdf. Accessed August 1, 2022.
  3. US Food and Drug Administration. Biosimilars action plan: balancing innovation and competition. July 2018.
  4. The Biosimilars Council. Biosimilars in the United States. http://biosimilarscouncil.org/wp-content/uploads/2019/03/Biosimilars-Council-Patient-Access-Study.pdf. Accessed August 1, 2022.
  5. US Food and Drug Administration. Biosimilar and Interchangeable Biologics. More Treatment Choices. 2021.